Jeffrey S. Ward
Download vCard

With 37 years of experience in intellectual property litigation, Jeff is a practiced, strategic advisor to pharmaceutical companies, API manufacturers, biotechnology firms, and chemical and manufacturing companies.

As a partner at Green, Griffith & Borg-Breen, he serves clients in counseling, litigation, and opinion matters primarily relating to pharmaceutical, chemical and biochemical products and processes.

Jeff has been trying pharmaceutical patent infringement cases brought pursuant to the Hatch-Waxman Act since the late 1980’s; during that time he has represented pharmaceutical companies and API manufacturers regarding 505(b)(2) and ANDA submissions on a wide variety of products. Jeff has acted as lead counsel and tried numerous Hatch-Waxman litigation matters to verdict. In addition, he has counseled clients regarding filing and regulatory strategies.

“We take a holistic approach to this work,” Jeff says, “It’s about more than just a single matter. We work with each client to develop creative strategies in line with its business objectives, and then execute those strategies. Over the years, I’ve been able to work with some of the same clients multiple times as they’ve moved from one business to another or their business has expanded. It’s gratifying to earn their trust and help them resolve issues that are important to them.”

Jeff has litigated patent and trade secret disputes relating to the pharmaceutical, chemical and mechanical arts in various federal courts throughout the U.S. and the International Trade Commission, including as lead counsel in a number of jury trials. He also has led many patent appeals, including arguing to the U.S. Court of Appeals for the Federal Circuit.

In addition, Jeff has significant experience advising clients with respect to opinion matters, due-diligence issues, patent prosecution strategy, freedom-to-operate opinions and FDA issues relating to product exclusivities and labeling.

Before joining Green Griffith, Jeff was a partner with Merchant & Gould.


University of Illinois College of Law, J.D.
University of Illinois, B.S., chemical engineering, with distinction

Court Admissions
  • State of Illinois Supreme Court
  • State of Wisconsin Supreme Court
  • U.S. Supreme Court
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Court of Appeals for the Third Circuit
  • U.S. Court of Appeals for the Seventh Circuit
  • U.S. District Court, Eastern District of Michigan
  • U.S. District Court, Northern District of Illinois (including Trial Bar)
  • U.S. District Court, Western District of Wisconsin
  • U.S. District Court, Central District of Illinois
  • U.S. District Court, District of Colorado
  • Registered Patent Attorney, U.S. Patent and Trademark Office, Reg. No. 32,774
  • Selected as a “Life Sciences Star,” LMG Life Sciences, 2020-2021
  • Selected by peers as a Leading Lawyer in Intellectual Property Law, Patent Law, and Trade Secrets/Unfair Competition Law, – Leading Lawyers Network, 2018-2021
  • Listed in Intellectual Asset Management’s (IAM) Patent 1000 in Litigation, 2013-2017, 2019-2021
  • Named as an “IP Star,” Managing IP, 2013-2015, 2018-2021
Representative Matters
  • Lipocine Inc. v. Clarus Therapeutics, Inc., No. 19-622-WCB (D. Del.) (infringement action regarding an oral testosterone undecanoate product)
  • Oxbo Int’l v. H&S Manufacturing, No. 15-cv-292 (W.D.Wis.) (represented patentee in infringement action regarding farm equipment)
  • Helsinn Healthcare v. Exela Pharma Sciences, No. 15-cv-7378 (D.N.J.) (505(b)(2) for palonosetron for injection)
  • Boehringer Ingelheim v. Aurobindo Pharma et al., No. 20-00023 (N.D.W. Va.) (ANDA for linagliptin tablets)
  • Boehringer Ingelheim v. Aurobindo Pharma et al., No. 15-5982 (D.N.J.) (ANDA for linagliptin tablets)
  • Boehringer Ingelheim v. Aurobindo Pharma et al., No. 19-1172 (Fed. Cir.) (ANDA for linagliptin tablets)
  • Par Pharmaceutical v. QuVa Pharma et al., No. 17-6115 (D.N.J.) (trade secret action regarding vasopressin for injection)
  • Pharmgate LLC v. Zoetis, Inc., No. 17-1889 (D.Minn.) (represented vaccine manufacturer regarding patents for PCV2 vaccines)
  • Sabert Corp. v. Placon Corp., No. 15-cv-182 (W.D. Wis.) (design patent infringement relating to food packaging containers)
  • Merck Sharp & Dohme v. Xellia Pharmaceuticals, ApS, No. 14-cv-199 (D.Del.) (ANDA for caspofungin for injection)
  • Pfizer, Inc. et al., v. CFT Pharmaceuticals, LLC, No. 14-cv-781 (D.Del.) (ANDA for tigecycline for injection)
  • Medicines Company v. Exela Pharma Sciences, LLC et al., No. 14-0058 (W.D.N.C.) (ANDA for bivalirudin for injection)
  • Sanofi et al. v. Unimark Remedies, Ltd., No. 14-876 (D.Del.) (ANDA for dronedarone tablets)
  • AbbVie, Inc., et al. v. Hikma Pharmaceutical Co., Ltd., et al., No. 13-cv-1557 (D.Del) (505(b)(2) application for paricalcitol for injection)
  • Cornerstone Therapeutics et al. v. Exela Pharma Sciences LLC, et al., No. 13-cv-275 (D.Del)(505(b)(2) application for nicardipine for injection)
  • Novartis Pharmaceutical Corporation v. Exela Pharma Sciences LLC, et al., No. 12-cv-3967 (D.N.J.) (ANDA for zoledronic acid for injection)
  • Novartis Pharmaceutical Corporation v. Hikma Pharmaceutica S.A., et al., No. 12-cv-3967 (D.N.J.) (ANDA for zoledronic acid for injection)
  • GlaxoSmithKline PLC, et al. v. Hikma Pharm. Co., et al., No. 12-cv-1965 (D.N.J.) (505(b)(2) application for argatroban for injection)
  • Cadence Pharmaceuticals, Inc. et al. v. Paddock Laboratories LLC. et al., No. 11-CV-733 (D. Del.) (ANDA for acetaminophen I.V.)
  • Cumberland Pharms. Inc. v. Paddock Labs., LLC, et al., No. 12-cv-619 (D. Del.) (ANDA for acetylcysteine I.V.)
  • Cumberland Pharms. Inc. v. Perrigo Co., No. 12-cv-6327 (N.D. Ill.) (ANDA for acetylcysteine I.V.)
  • AstraZeneca Pharmaceuticals et al. v. Aurobindo Pharmaceuticals Ltd. et al., No. 2011-1183 (Fed. Cir. Feb 9, 2012) (ANDA for rosuvastatin calcium)
  • AstraZeneca Pharmaceuticals et al. v. Aurobindo Pharmaceuticals Ltd. et al., No. 2010-1460 (Fed. Cir.) (ANDA for rosuvastatin calcium)
  • Novo-Nordisk, Inc. et al. v. Aurobindo Pharma Ltd., No. 12-1388 (Fed. Cir.); No. 12-cv-1-26 (D.N.J.) (ANDA for repaglinide tablets)
  • Braintree Labs, Inc. v. Paddock Labs., Inc., No. 11-cv-4568 (D.N.J) (ANDA for sodium sulfate/potassium sulfate/magnesium sulfate osmotic laxative preparation)
  • Allergan et al. v. Watson Laboratories-Florida, Sandoz, Inc., and Paddock Laboratories, Inc., No. 09-511-GMS (Consolidated) (D. Del.) (ANDA for trospium ER capsules)
  • Purdue Pharmaceuticals et al v. Paddock Laboratories, Inc., No.09-666-KAJ and No. 10-129-KAJ (D. Del.) (ANDA for tramadol ER tablets)
  • Sanofi-Aventis et al. v. Aurolife Pharma LLC, et al., No. 10-cv-5801 (D.N.J.) (ANDA for fexofenadine tablets)
  • Takeda Pharm. Co. Ltd., et al. v. Aurobindo Pharma Ltd., et al., No. 10-247 (S.D.N.Y.) (ANDA for pioglitazone tablets)
  • In re: Rosuvastatin Calcium Patent Litigation, MDL No. 08-1949 (D. Del.) (ANDA for rosuvastatin calcium tablets)
  • AstraZeneca Pharmaceuticals LP et al v. Aurobindo Pharma Limited, Inc. et al., No. 07-810 (D. Del.) (ANDA for rosuvastatin calcium tablets)
  • Future Fibre Technologies Pty. Ltd. v. Optellios, Inc., No. 08-CV-600 (M.D. Fla.) (inventorship dispute regarding laser-based security systems)
  • Future Fibre Technologies Pty. Ltd. v. Optellios, Inc., No. 09-CV-346 (D. Del.) (inventorship dispute regarding laser-based security systems)
  • Riezler et al. v. Allen et al., No. 08-CV-332 (D. Colo.); No. 09-1528 (Fed. Cir.) (inventorship dispute regarding patents relating to metabolites)
  • Invitrogen Corporation v. Oxford Biomedical Research, Inc. and Vanderbilt University, No. 08-CV-599 (W.D. Wis.) (patent infringement action)
  • Z Trim Holdings, Inc. v. Fiberstar, Inc., No. 07-CV-161 (W.D. Wis.) (patent infringement action regarding food additive)
  • Z Trim Holdings, Inc. v. Fiberstar, Inc., No. 06-CV-361 (W.D. Wis.) (patent infringement action regarding food additive)
  • Forest Laboratories, Inc. v. Ivax Pharmaceuticals, Inc., et al., 438 F. Supp. 3d 479 (D. Del. 2006) (ANDA for escitalopram tablets)
  • Medichem S.A. v. Rolabo, S.L., 437 F.3d 1157 (Fed. Cir. 2006) (priority case regarding a process for making a pharmaceutical product)
  • Eli Lilly & Co. v. Zenith Goldline Pharms., Inc., 364 F. Supp. 2d 820 (S.D. Ind. 2005) (ANDA for olanzapine tablets)
  • Kraft Foods, Inc. v. Int’l. Trading Co., 203 F.3d 1362 (Fed. Cir. 2000) (patent infringement case regarding food product packaging)
  • Glaxo, Inc. v. Novopharm Ltd., 931 F. Supp. 1280 (E.D.N.C.1996) (ANDA for ranitidine HCl tablets)
  • Glaxo, Inc. v. Novopharm Ltd., 52 F.3d 1043 (Fed. Cir. 1995) (ANDA for ranitidine HCl tablets)
  • Pall Corp. v. Micron Separations, Inc., 66 F.3d 1211 (Fed. Cir. 1995) (patent infringement case regarding membrane filters)
  • Burroughs Wellcome Co. v. Barr Labs and Novopharm Ltd., 40 F.3d 1223 (Fed. Cir. 1994) (ANDA for AZT tablets)
  • Cardinal Chemical Co. v. Morton Int’l, Inc., 508 U.S. 83 (1993) (patent infringement case regarding chemical additive)
Speaking Engagements and Presentations
  • Speaker/panelist at the Pharma IPR Conference, Mumbai, India—2013, 2014, 2016, 2017

Powerful advice. Persuasive advocacy.